Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Data from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Data from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Data from Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas

Data from Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas

Figure S1 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Figure S2 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Figure S4 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Figure S6 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Figure S7 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Higher polygenic risk for melanoma is associated with improved survival

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Supplementary Figure Legends from Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas

Supplementary Figure S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Figure S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Figure S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Figure S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Figure S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Figure S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Figure S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Figure S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Figure S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Figures and Tables from Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas

Supplementary Figures and Tables from Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas

Supplementary Results1 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Table S10 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S11 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S12 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S13 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S14 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S15 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S16 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S2 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S3 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S4 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S5 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S7 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S8 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Table S9 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors